In a stern warning, the US Food and Drug Administration (USFDA) has issued a letter to Granules India, highlighting serious lapses at its formulations manufacturing plant in Telangana. The notice criticizes the company for failing to maintain its buildings, crucial for drug storage, and for neglecting essential cleaning and maintenance procedures for equipment.
About the Author
